 |
|
|
Important Notice: The Forum does not endorse any medical
product or therapy. ALL medications and supplements
should be taken ONLY under the supervision of a physician,
due to the possibility of side-effects, drug interactions,
etc.
|
Name:
|
Ibuprofen
|
|
Other Names:
|
Advil™, Motrin™, Nuprin™
|
|
Development Status:
|
investigational in U.S.
|
|
FDA Phase:
|
Discontinued
|
|
Primary Medical Role:
|
A nonsteroidal anti-inflammatory drug (NSAIDs), Ibuprofen
is used to reduce the fever, pain, inflammation, and
stiffness caused by many conditions, such as
osteoarthritis, rheumatoid arthritis, and abdominal cramps
associated with menstruation.
|
|
Role in Alzheimer's Disease:
|
May aid in preventing or delaying the onset of Alzheimer's
disease by decreasing inflammation in the brain.
|
|
Pharmacological Role:
|
Reduces prostaglandin activity by inhibiting prostaglandin
synthetase. Has anti-inflammatory, analgesic ,and some
antipyretic activity.
|
|
Contraindications:
|
History of allergic reactions to Ibuprofen other non-
steriodal anti-inflammatory drugs and aspirin.
|
|
Side Effects:
|
Stomach distress, gastrointestinal bleeding.
|
|
Evidence pro its efficacy:
|
The evidence that nonsteroidal anti-inflammatory
medications (NSAIDs) help Alzheimer's patients have been
retrospective. In other words, certain flaws in the
ointments exist. However, these studies suggest that the
progression of Alzheimer's disease is delayed in those
taking NSAIDs. Incidence in these patients is described as
being cut as much as in half.
|
|
Notes:
|
A Phase IV study to investigate the effects of NSAIDs on
Abeta peptide was completed in 2008 NCT00046358
followed by a Phase I study to examine the effect of
ibuprofen on AD biomarkers
NCT00239746
which is ongoing.
This entry was last updated October 7, 2010.
|
Tabet N, Feldmand H. Ibuprofen for Alzheimer's disease
(Cochrane Review). Cochrane Database Syst Rev. 2003.
CD004031. Abstract
Jantzen PT, Connor KE, DiCarlo G, Wenk GL, Wallace JL,
Rojiani AM, Coppola D, Morgan D, Gordon MN. Microglial
activation and beta -amyloid deposit reduction caused by a
nitric oxide-releasing nonsteroidal anti-inflammatory drug
in amyloid precursor protein plus presenilin-1 transgenic
mice. J Neurosci. 2002 Mar 15;22(6):2246-54.
Abstract
Blasko I, Apochal A, Boeck G, Hartmann T, Grubeck-
Loebenstein B, Ransmayr G. Ibuprofen decreases cytokine-
induced amyloid beta production in neuronal cells.
Neurobiol Dis. 2001 Dec;8(6):1094-101. Abstract
Lim GP, Yang F, Chu T, Gahtan E, Ubeda O, Beech W,
Overmier JB, Hsiao-Ashec K, Frautschy SA, Cole GM.
Ibuprofen effects on Alzheimer pathology and open field
activity in APPsw transgenic mice. Neurobiol Aging. 2001
Nov-Dec;22(6):983-91. Abstract
Mitchell JA, Warner TD. Cyclo-oxygenase-2: pharmacology,
physiology, biochemistry and relevance to NSAID therapy.
Br J Pharmacol. 1999 Nov;128(6):1121-32. Abstract
Stratman NC, Carter DB, Sethy VH. Ibuprofen: effect on
inducible nitric oxide synthase. Brain Res Mol Brain Res.
1997 Oct 15;50(1-2):107-12. Abstract
Stewart WF, Kawas C, Corrada M, Metter EJ. Risk of
Alzheimer's disease and duration of NSAID use. Neurology.
1997 Mar;48(3):626-32. Abstract
Rich JB, Rasmusson DX, Folstein MF, Carson KA, Kawas C,
Brandt J. Nonsteroidal anti-inflammatory drugs in
Alzheimer's disease. Neurology. 1995 Jan;45(1):51-5. Abstract
|
|
|
|
|
Home
